|
"hsu c"的相關文件
顯示項目 1-10 / 881 (共89頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-09-17 |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration
|
Lin, YJ;Ou, DL;Su, YY;Hsu, CL;Hsiao, CF;Ko, BS;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Jeng, YM;Lee, WC;Chou, SC;Chen, TW;Chiu, CF;Shiuan, L, Jr.;Hsieh, CH;Lee, CC;Shen, YS;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2025-07 |
Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer
|
Brunetti, L;D'Alessio, A;Fulgenzi, CAM;Yarchoan, M;Marron, T;Blanter, J;Torkpour, A;Lombardi, P;Baretti, M;Crowley, F;Hsu, C;Cortellini, A;Su, YY;Lee, PC;Eid, JR;Kaseb, A;Pinato, DJ |
| 國家衛生研究院 |
2025-03-25 |
Modification of magnetite-doped NH2-MIL-100(Fe) by aliphatic C8 or C18 carbon chain with excellent hydrophobicity for effective protein separation and purification
|
Gu, Y;Hsu, C;Chen, W;Wu, K |
| 國家衛生研究院 |
2024-12-19 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer[Erratum:ESMO Open. 2024 Aug 06;9(8):Article number 103647.]
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國家衛生研究院 |
2024-11 |
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis
|
D'Alessio, A;Stefanini, B;Blanter, J;Adegbite, B;Crowley, F;Yip, V;Slater, S;Fulgenzi, CAM;Celsa, C;Manfredi, GF;Pai, M;Goldin, RD;Ward, SC;Fiel, MI;Shu, DH;Su, YY;Cortellini, A;Baretti, M;Anders, R;Yarchoan, M;Hsu, C;Marron, TU;Pinato, DJ |
| 國家衛生研究院 |
2024-10 |
TCOG T3221 study: The registry of genetic alterations of Taiwan biliary tract cancer
|
Chiang, N;Hsu, C;Chen, J;Dai, M;Bai, L;Yen, C;Wang, T;Hsieh, Y;Lin, J;Chiu, T;Cheng, H;Yang, Y;Hsiao, C;Chen, L;Chen, M |
| 國家衛生研究院 |
2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國家衛生研究院 |
2024-06-21 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
|
Tsai, HJ;Yang, SH;Hsiao, CF;Kao, HF;Su, YY;Shan, YS;Yen, CJ;Du, JS;Hsu, C;Wu, IC;Chen, LT |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)
|
Chen, TWW;Hsu, CL;Wu, YC;Ou, DL;Su, YY;Cheng, AL;Hsu, C |
顯示項目 1-10 / 881 (共89頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
